Valproic Acid and Lithium Meditate Anti-Inflammatory Effects by Differentially Modulating Dendritic Cell Differentiation and Function

Journal of Cellular Physiology

Volumn 232, Issue 5, 2017, Pages 1176-1186

  Leu, Sy Jye ^a,b,c   Yang, Yi Yuan ^c,d   Liu, Hsing Cheng ^a,e   Cheng, Chieh Yu ^b   Wu, Yu Chen ^f   Huang, Ming Chyi ^a,e   Lee, Yuen Lun ^a,b   Chen, Chi Ching ^g   Shen, Winston W ^a   Liu, Ko Jiunn ^c,f,h  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g Landseed Hospital   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; ENTINOSTAT; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; LITHIUM; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; VALPROIC ACID; VORINOSTAT; ANTIINFLAMMATORY AGENT; CYTOKINE; LEUKOCYTE ANTIGEN; LIPOPOLYSACCHARIDE; LITHIUM CHLORIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIPID STORAGE; LYMPHOCYTE ACTIVATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; T LYMPHOCYTE; TH17 CELL; ANIMAL; ARTHRITIS, EXPERIMENTAL; BOVINE; CELL POLARITY; CYTOLOGY; DRUG EFFECTS; INFLAMMATION; LIPID METABOLISM; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ARTHRITIS, EXPERIMENTAL; CATTLE; CELL DIFFERENTIATION; CELL POLARITY; CYTOKINES; DENDRITIC CELLS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; LIPID METABOLISM; LIPOPOLYSACCHARIDES; LITHIUM CHLORIDE; MICE; MONOCYTES; TH17 CELLS; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; VALPROIC ACID;

EID: 85000730430     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25604     Document Type: Article

References (58)

1. Alda M. 2015. Lithium in the treatment of bipolar disorder: Pharmacology and pharmacogenetics. Mol Psychiatry 20:661–670.
2. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. 2004. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord 82:309–313.
3. Brand DD, Latham KA, Rosloniec EF. 2007. Collagen-induced arthritis. Nat Protoc 2:1269–1275.
4. Bricard G, Porcelli SA. 2007. Antigen presentation by CD1 molecules and the generation of lipid-specific T cell immunity. Cell Mol Life Sci 64:1824–1840.
5. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q. 2007. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109:1123–1130.
6. Chauvistre H, Kustermann C, Rehage N, Klisch T, Mitzka S, Felker P, Rose-John S, Zenke M, Sere KM. 2014. Dendritic cell development requires histone deacetylase activity. Eur J Immunol 44:2478–2488.
7. Chen L, Meng D, Zhao L, Liu R, Bai P, Wang L, Xiao J. 2015. Selective colorectal cancer cell lysates enhance the immune function of mature dendritic cells in vitro. Mol Med Rep 11:1877–1884.
8. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS. 2006. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11:1116–1125.
9. Chiu CT, Wang Z, Hunsberger JG, Chuang DM. 2013. Therapeutic potential of mood stabilizers lithium and valproic acid: Beyond bipolar disorder. Pharmacol Rev 65:105–142.
10. Chung CY, Ysebaert D, Berneman ZN, Cools N. 2013. Dendritic cells: Cellular mediators for immunological tolerance. Clin Dev Immunol 2013:972865.
11. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. 2013. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 10:CD003196.
12. de Araujo EG, da Silva GM, Dos Santos AA. 2009. Neuronal cell survival: The role of interleukins. Ann N Y Acad Sci 1153:57–64.
13. Doncarli A, Stasiuk LM, Fournier C, Abehsira-Amar O. 1997. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur J Immunol 27:1451–1458.
14. Gobbi G, Janiri L. 2006. Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl) 185:255–262.
15. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978.
16. Henningsson L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Berg WB, van de Loo FA, Gjertsson I. 2012. Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PLoS ONE 7:e49731.
17. Kapoor S. 2015. Tumor growth mitigating effects of valproic acid in systemic malignancies. J Thyroid Res 2015:540183.
18. Kim AJ, Shi Y, Austin RC, Werstuck GH. 2005. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci 118:89–99.
19. Kim HJ, Chuang DM. 2014. HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: Potential roles of oligodendrogenesis, VEGF, and anti-inflammation. Am J Transl Res 6:206–223.
20. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, Steinbusch HW. 2004. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 129:267–272.
21. Kostrouchova M, Kostrouch Z. 2007. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53:37–49.
22. Kozlovsky N, Amar S, Belmaker RH, Agam G. 2006. Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol 9:337–342.
23. Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE, Jr., Leverich GS, Rush AJ, Suppes T, Pollio C, Drexhage HA. 2002. High rate of autoimmune thyroiditis in bipolar disorder: Lack of association with lithium exposure. Biol Psychiatry 51:305–311.
24. Lagace DC, Nachtigal MW. 2004. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 279:18851–18860.
25. Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, Mapara MY. 2006. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 34:776–787.
26. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. 2002. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99:2995–3000.
27. Liu KJ, Lee YL, Yang YY, Shih NY, Ho CC, Wu YC, Huang TS, Huang MC, Liu HC, Shen WW, Leu SJ. 2011. Modulation of the development of human monocyte-derived dendritic cells by lithium chloride. J Cell Physiol 226:424–433.
28. Martin M, Rehani K, Jope RS, Michalek SM. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777–784. Epub 2005 Jul 2010.
29. Mawatari T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K, Makino I, Nakagawara H, Miyashita T, Tajima H, Takamura H, Fushida S, Ohta T. 2015. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol 47:2073–2081.
30. Morel PA, Butterfield LH. 2015. Dendritic cell control of immune responses. Front Immunol 6:42.
31. Naganska E, Matyja E, Taraszewska A, Rafalowska J. 2015. Protective effect of valproic acid on cultured motor neurons under glutamate excitotoxic conditions. Ultrastructural study. Folia Neuropathol 53:309–316.
32. Nassar A, Azab AN. 2014. Effects of lithium on inflammation. ACS Chem Neurosci 5:451–458.
33. Nencioni A, Beck J, Werth D, Grunebach F, Patrone F, Ballestrero A, Brossart P. 2007. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 13:3933–3941.
34. Oh J, Shin JS. 2015. The role of dendritic cells in central tolerance. Immune Netw 15:111–120.
35. Ohmura Y, Tsutsui-Kimura I, Kumamoto H, Minami M, Izumi T, Yamaguchi T, Yoshida T, Yoshioka M. 2012. Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats. Psychopharmacology (Berl) 219:421–432.
36. Okada A, Aoki Y, Kushima K, Kurihara H, Bialer M, Fujiwara M. 2004. Polycomb homologs are involved in teratogenicity of valproic acid in mice. Birth Defects Res A Clin Mol Teratol 70:870–879.
37. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, Hong JS. 2005. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: Role of microglia. Brain Res Mol Brain Res 134:162–169.
38. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734–36741.
39. Pietrosimone KM, Jin M, Poston B, Liu P. 2015. Collagen-induced arthritis: A model for murine autoimmune arthritis. Bio Protoc 5.
40. Pilcher HR. 2003. Drug research: The ups and downs of lithium. Nature 425:118–120.
41. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JL. 2004. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101:3921–3926.
42. Rodionova E, Conzelmann M, Maraskovsky E, Hess M, Kirsch M, Giese T, Ho AD, Zoller M, Dreger P, Luft T. 2007. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood 109:1584–1592.
43. Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS. 2015. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. J Affect Disord 188:149–159.
44. Said A, Weindl G. 2015. Regulation of dendritic cell function in inflammation. J Immunol Res 2015:743169.
45. Shen WW, Liu HC, Yang YY, Lin CY, Chen KP, Yeh TS, Leu SJ. 2006. Anti-heat shock protein 90 is increased in acute mania. Aust N Z J Psychiatry 40:712–716.
46. Shiah IS, Yatham LN, Yeh CB, Ravindran AV. 2005. Effect of valproate on plasma levels of interleukin-6 in healthy male humans. Int Clin Psychopharmacol 20:295–298.
47. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. 2003. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 18:73–79.
48. Srivastava NK, Sharma S, Purusottam RN, Sinha N, Singh R, Sharma D. 2014. Abnormal lipid metabolism in collagen-induced arthritis rat model: In vitro, high resolution NMR spectroscopy based analysis. Indian J Exp Biol 52:673–682.
49. Suda S, Katsura K, Kanamaru T, Saito M, Katayama Y. 2013. Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation. Eur J Pharmacol 707:26–31.
50. Szatmari I, Gogolak P, Im JS, Dezso B, Rajnavolgyi E, Nagy L. 2004. Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity 21:95–106.
51. Tanaka S, Toki T, Akimoto T, Morishita K. 2013. Lipopolysaccharide accelerates collagen-induced arthritis in association with rapid and continuous production of inflammatory mediators and anti-type II collagen antibody. Microbiol Immunol 57:445–454.
52. Verrotti A, Basciani F, Trotta D, Greco R, Morgese G, Chiarelli F. 2001. Effect of anticonvulsant drugs on interleukins-1, -2 and -6 and monocyte chemoattractant protein-1. Clin Exp Med 1:133–136.
53. Werstuck GH, Kim AJ, Brenstrum T, Ohnmacht SA, Panna E, Capretta A. 2004. Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds. Bioorg Med Chem Lett 14:5465–5467.
54. West AC, Smyth MJ, Johnstone RW. 2014. The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology 3:e27414.
55. Wu S, Luo H, Xiao X, Zhang H, Li T, Zuo X. 2014. Attenuation of collagen induced arthritis via suppression on Th17 response by activating cholinergic anti-inflammatory pathway with nicotine. Eur J Pharmacol 735:97–104.
56. Xu X, Muller-Taubenberger A, Adley KE, Pawolleck N, Lee VW, Wiedemann C, Sihra TS, Maniak M, Jin T, Williams RS. 2007. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell 6:899–906.
57. Ye L, Wen Z, Li Y, Chen B, Yu T, Liu L, Zhang J, Ma Y, Xiao S, Ding L, Li L, Huang Z. 2014. Interleukin-10 attenuation of collagen-induced arthritis is associated with suppression of interleukin-17 and retinoid-related orphan receptor gammat production in macrophages and repression of classically activated macrophages. Arthritis Res Ther 16:R96.
58. Zajonc DM, Kronenberg M. 2007. CD1 mediated T cell recognition of glycolipids. Curr Opin Struct Biol 17:521–529.